MA56504A - Dérivés de pyridin-3-yle - Google Patents
Dérivés de pyridin-3-yleInfo
- Publication number
- MA56504A MA56504A MA056504A MA56504A MA56504A MA 56504 A MA56504 A MA 56504A MA 056504 A MA056504 A MA 056504A MA 56504 A MA56504 A MA 56504A MA 56504 A MA56504 A MA 56504A
- Authority
- MA
- Morocco
- Prior art keywords
- yle
- pyridin
- derivatives
- yle derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Debugging And Monitoring (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019065963 | 2019-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56504A true MA56504A (fr) | 2022-04-27 |
Family
ID=71105482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056504A MA56504A (fr) | 2019-06-18 | 2020-06-17 | Dérivés de pyridin-3-yle |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12479820B2 (fr) |
| EP (1) | EP3986884A1 (fr) |
| JP (1) | JP7494222B2 (fr) |
| KR (1) | KR102786045B1 (fr) |
| CN (1) | CN114026082B (fr) |
| AR (1) | AR119162A1 (fr) |
| AU (1) | AU2020298014B2 (fr) |
| BR (1) | BR112021025236A2 (fr) |
| CA (1) | CA3143618A1 (fr) |
| CL (1) | CL2021003348A1 (fr) |
| IL (1) | IL288950B2 (fr) |
| MA (1) | MA56504A (fr) |
| MX (1) | MX2021015727A (fr) |
| PH (1) | PH12021553178A1 (fr) |
| SG (1) | SG11202111162PA (fr) |
| TW (1) | TWI845708B (fr) |
| WO (1) | WO2020254408A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230243T1 (hr) | 2018-06-07 | 2023-04-14 | Idorsia Pharmaceuticals Ltd | Alkoksi supstituirani derivati piridinila kao antagonisti receptora lpa1 i njihova uporaba u liječenju fibroze |
| CA3160410A1 (fr) * | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combinaison d'un antagoniste du recepteur lpa1 de l'azetidine avec de la pirfenidone et/ou du nintedanib destinee a etre utilisee dans le traitement de maladies fibrotiques |
| WO2025169931A1 (fr) * | 2024-02-05 | 2025-08-14 | Ｕｂｅ株式会社 | Composé carboxamide |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130088C (fr) | 1960-03-14 | |||
| EP0661284A1 (fr) * | 1992-09-18 | 1995-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation medicinale |
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| WO2001032173A1 (fr) | 1999-10-29 | 2001-05-10 | Yamanouchi Pharmaceutical Co., Ltd. | Inhibiteurs de neurocytotoxicite de l'acide kainique |
| WO2001077077A1 (fr) | 2000-04-10 | 2001-10-18 | Novartis Ag | Derives d'(hetero)aryl-carboxamide en tant qu'inhibiteurs de la proteine microsomale de transfert des triglycerides (mtp) et de la secretion d'apolipoproteine b (apo b) |
| DE60234318D1 (de) | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| US7435824B2 (en) | 2002-04-19 | 2008-10-14 | Bristol-Myers Squibb Company | Prodrugs of potassium channel inhibitors |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| EP1628666B1 (fr) | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Composes et leurs utilisations pour la modulation de l'amyloide-beta |
| EP1670787B1 (fr) | 2003-09-11 | 2012-05-30 | iTherX Pharma, Inc. | Inhibiteurs des cytokines |
| EP1679069A4 (fr) | 2003-10-21 | 2009-05-13 | Dainippon Sumitomo Pharma Co | Nouveau derive de piperidine |
| US20070105902A1 (en) * | 2003-11-12 | 2007-05-10 | Lindsley Craig W | 4-Phenyl piperdine sulfonyl glycine transporter inhibitors |
| WO2005049605A1 (fr) | 2003-11-18 | 2005-06-02 | Warner-Lambert Company Llc | Derives antibacteriens d'aminoquinazolidinedione |
| WO2006091862A2 (fr) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Inhibiteurs des cytokines et utilisation therapeutique |
| TWI377198B (en) | 2005-08-24 | 2012-11-21 | Eisai R&D Man Co Ltd | Novel pyridine derivatives and pyrimidine derivatives (3) |
| WO2007058990A2 (fr) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapie a base d’inhibiteurs de cytokine |
| CA2691214A1 (fr) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapie a base d'inhibiteurs de cytokine |
| JP5164510B2 (ja) | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
| US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| WO2009051715A1 (fr) | 2007-10-18 | 2009-04-23 | Merck & Co., Inc. | Modulateurs allostériques positifs du récepteur m1 de la quinolizidinone |
| US8193202B2 (en) | 2008-04-21 | 2012-06-05 | Lexicon Pharmaceuticals, Inc. | LIMK2 inhibitors, compositions comprising them, and methods of their use |
| CN105418450A (zh) | 2008-05-05 | 2016-03-23 | 赛诺菲-安万特 | 酰基氨基取代的稠合环戊烷羧酸衍生物及它们作为药物的用途 |
| AU2009286734A1 (en) | 2008-08-26 | 2010-03-04 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
| RU2563639C2 (ru) * | 2009-09-25 | 2015-09-20 | Астеллас Фарма Инк. | Замещенные соединения амида |
| KR101508862B1 (ko) | 2010-08-05 | 2015-04-07 | 조에티스 엘엘씨 | 구충제로서 이속사졸린 유도체 |
| TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為ｍＰＧＥＳ－１抑制物的三環化合物 |
| SG191041A1 (en) | 2010-12-07 | 2013-08-30 | Amira Pharmaceuticals Inc | Polycyclic lpa1 antagonist and uses thereof |
| EP2651930B1 (fr) | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Inhibiteurs biarylamide de production de leukotriènes |
| HRP20160601T1 (hr) | 2011-03-10 | 2016-07-01 | Zoetis Services Llc | Spirociklički derivati izoksazolina kao antiparazitska sredstva |
| IN2014MN01433A (fr) | 2011-12-21 | 2015-07-03 | Ardelyx Inc | |
| US20140148484A1 (en) | 2012-11-23 | 2014-05-29 | Boehringer Ingelheim International Gmbh | Pyrazole compounds for treating hairloss |
| EP2970200A1 (fr) * | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Inhibiteurs de pyridine cdk9 kinase |
| JP2017500287A (ja) * | 2013-11-06 | 2017-01-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体 |
| AR108185A1 (es) | 2016-04-06 | 2018-07-25 | Abbvie Inc | Amidas terciarias y método para su uso |
| HRP20230243T1 (hr) * | 2018-06-07 | 2023-04-14 | Idorsia Pharmaceuticals Ltd | Alkoksi supstituirani derivati piridinila kao antagonisti receptora lpa1 i njihova uporaba u liječenju fibroze |
| CA3160410A1 (fr) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combinaison d'un antagoniste du recepteur lpa1 de l'azetidine avec de la pirfenidone et/ou du nintedanib destinee a etre utilisee dans le traitement de maladies fibrotiques |
-
2020
- 2020-06-16 AR ARP200101686A patent/AR119162A1/es unknown
- 2020-06-17 JP JP2021574814A patent/JP7494222B2/ja active Active
- 2020-06-17 US US17/620,520 patent/US12479820B2/en active Active
- 2020-06-17 PH PH1/2021/553178A patent/PH12021553178A1/en unknown
- 2020-06-17 AU AU2020298014A patent/AU2020298014B2/en active Active
- 2020-06-17 SG SG11202111162PA patent/SG11202111162PA/en unknown
- 2020-06-17 MX MX2021015727A patent/MX2021015727A/es unknown
- 2020-06-17 CA CA3143618A patent/CA3143618A1/fr active Pending
- 2020-06-17 MA MA056504A patent/MA56504A/fr unknown
- 2020-06-17 CN CN202080044333.8A patent/CN114026082B/zh active Active
- 2020-06-17 BR BR112021025236A patent/BR112021025236A2/pt unknown
- 2020-06-17 EP EP20733601.7A patent/EP3986884A1/fr active Pending
- 2020-06-17 IL IL288950A patent/IL288950B2/en unknown
- 2020-06-17 KR KR1020227001133A patent/KR102786045B1/ko active Active
- 2020-06-17 TW TW109120315A patent/TWI845708B/zh active
- 2020-06-17 WO PCT/EP2020/066767 patent/WO2020254408A1/fr not_active Ceased
-
2021
- 2021-12-15 CL CL2021003348A patent/CL2021003348A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL288950A (en) | 2022-02-01 |
| BR112021025236A2 (pt) | 2022-02-01 |
| AU2020298014B2 (en) | 2026-02-05 |
| JP2022537177A (ja) | 2022-08-24 |
| JP7494222B2 (ja) | 2024-06-03 |
| KR102786045B1 (ko) | 2025-03-24 |
| IL288950B2 (en) | 2025-03-01 |
| KR20220020921A (ko) | 2022-02-21 |
| CN114026082A (zh) | 2022-02-08 |
| WO2020254408A1 (fr) | 2020-12-24 |
| IL288950B1 (en) | 2024-11-01 |
| AR119162A1 (es) | 2021-12-01 |
| TWI845708B (zh) | 2024-06-21 |
| CN114026082B (zh) | 2024-06-07 |
| MX2021015727A (es) | 2022-01-24 |
| US12479820B2 (en) | 2025-11-25 |
| US20220251068A1 (en) | 2022-08-11 |
| SG11202111162PA (en) | 2021-11-29 |
| TW202115011A (zh) | 2021-04-16 |
| CL2021003348A1 (es) | 2022-09-23 |
| CA3143618A1 (fr) | 2020-12-24 |
| PH12021553178A1 (en) | 2022-11-07 |
| EP3986884A1 (fr) | 2022-04-27 |
| AU2020298014A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3958977T (pt) | Derivados de camptotecina | |
| IL292753A (en) | Compounds | |
| IL292161A (en) | New methylquinazolinone derivatives | |
| EP3717479C0 (fr) | Dérivés de thiazole microbiocides | |
| DK4067344T3 (da) | Cycloalkylurinstofderivat | |
| EP4013751C0 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| LT3830085T (lt) | Deuterinti lanifibranoro dariniai | |
| EP4037676A4 (fr) | Dérivés cannabinoïdes | |
| EP4073033A4 (fr) | Dérivés cannabinoïdes | |
| EP3999490A4 (fr) | Dérivés cannabinoïdes | |
| EP3997095A4 (fr) | Dérivés cannabinoïdes | |
| EP4077334C0 (fr) | Dérivés furoindazole | |
| EP3457851A4 (fr) | Dérivés de sobétirome | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| EP4021904C0 (fr) | Dérivés d'alpha-d-galactopyranoside | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| EP3885347A4 (fr) | Dérivé de dihydropyrrolopyrazole | |
| IL304774A (en) | Enhanced sophorolipid derivatives | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| EP3371163A4 (fr) | Dérivés de pyrrolidine | |
| EP4013441A4 (fr) | Formulations de larazotide | |
| MA56504A (fr) | Dérivés de pyridin-3-yle | |
| PT3796975T (pt) | Derivados de sulfonilaminobenzamida | |
| EP3472151A4 (fr) | Dérivés de prolinamide carbocycliques | |
| DK3894410T3 (da) | Substituerede xanthinderivater |